用TACE,TKI和ICI进行转化疗法,用于不可切除的BCLC B阶段和C阶段肝细胞癌
Zhuoran Wang1,2,3,4, Cunzhen Zhang1, Jianhua Yin2,3,4
1Department of Hepatic Surgery I (Ward I) Shanghai Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai, China.
Frontiers in immunology
|June 25, 2025
概括
结合TACE,TKI和ICI的三重疗法显示,对不可切除的肝细胞癌 (uHCC) 的转化率有所改善. 虽然整体存活率和无复发存活率与其他治疗方法相比,但这种疗法为HHCC转化疗法提供了有前途的选择.
科学领域:
- 肝胆道手术 肝胆道手术
- 医学瘤学 医学瘤学
- 胃肠病学 胃肠病学
背景情况:
- 肝细胞癌 (HCC) 通常在晚期呈现,限制了手术选择.
- 转化疗法旨在使无法切除的HCC (uHCC) 易于进行治疗性手术.
- 现有的转换疗法具有可变的疗效,需要进一步研究.
研究的目的:
- 为了评估TACE+TKI+ICI三重疗法对HCC转换的疗效.
- 为了比较这种三重疗法的预后与文献中的其他转化策略.
- 确定三重疗法是否代表HHCC的最佳转换方案.
主要方法:
- 对57名患有BCLC B和C阶段HCC的患者进行了回顾性分析,这些患者接受了TACE+TKI+ICI转化疗法.
- 9项研究的综合文献综述 (560名患者) 关于HHCC的转化疗法.
- 转化率,疾病控制,整体存活率和无复发存活率的比较.
主要成果:
- 在研究队列中,TACE+TKI+ICI三重疗法实现了14.0%的转化率和66.7%的疾病控制率 (DCR).
- 与文献数据相比,三重疗法的转化率明显高于文献数据.
- 总生存率 (OS) 和无复发生存率 (RFS) 与其他转换方式相似.
结论:
- TACE+TKI+ICI三重疗法显示,HHCC患者的转化率有所提高.
- 这一制度显示出作为HHCC有效转换战略的潜力.
- 需要进一步的研究,以充分阐明三重组治疗的长期生存益处.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.0K
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.4K
相关概念视频
01:27Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K